Ubidecarenone compositions and capsules containing the same
    1.
    发明申请
    Ubidecarenone compositions and capsules containing the same 审中-公开
    Ubidecarenone组合物和含有它们的胶囊

    公开(公告)号:US20030108600A1

    公开(公告)日:2003-06-12

    申请号:US10222925

    申请日:2002-08-19

    摘要: To provide Ubidecarenone compositions being excellent in absorbability into the body, highly stable at low temperatures, keeping clear external appearance, and being liquid at ordinary temperature. Ubidecarenone is dissolved in oils by which the accumulation of fats in the body is low, for example, triglyceride, which contains a short chain fatty acid as constitutive fatty acid, preferably SALATRIM, or diglyceride, for example, a hybrid glyceride composed of a middle chain fatty acid and a long chain fatty acid.

    摘要翻译: 为了提供对身体的吸收性优异的乌尼可龙酮组合物,在低温下高度稳定,外观保持清晰,在常温下为液体。 Ubidecarenone溶解在油中,脂肪在体内的积累较少,例如甘油三酸酯,其含有短链脂肪酸作为组成型脂肪酸,优选SALATRIM或甘油二酯,例如由中间体组成的杂种甘油酯 链脂肪酸和长链脂肪酸。

    Antiviral medication
    3.
    发明申请
    Antiviral medication 审中-公开
    抗病毒药物

    公开(公告)号:US20020071863A1

    公开(公告)日:2002-06-13

    申请号:US09733847

    申请日:2000-12-08

    IPC分类号: A61K009/66 A61K009/24

    CPC分类号: A61K9/0004

    摘要: A pharmaceutical composition comprising a liquid antiviral formulation is disclosed. Additionally, a dosage form and a method for administering an antiviral pharmaceutical composition are disclosed.

    摘要翻译: 公开了包含液体抗病毒制剂的药物组合物。 另外,公开了用于施用抗病毒药物组合物的剂型和方法。

    USE OF NANODISPERSIONS IN PHARMACEUTICAL END FORMULATIONS
    6.
    发明申请
    USE OF NANODISPERSIONS IN PHARMACEUTICAL END FORMULATIONS 有权
    在药物末端制剂中使用纳米尺度

    公开(公告)号:US20030190347A1

    公开(公告)日:2003-10-09

    申请号:US09306006

    申请日:1999-05-06

    摘要: A description is given of the use of a nanodispersion, which comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (null) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (null) adding the liquid obtained in step (null) to the water phase of the pharmaceutical end formulations, steps (null) and (null) being carried out without any additional supply of energy. The nanodispersions used according to this invention are suitable as transport vehicles for pharmaceutical active agents.

    摘要翻译: 给出了使用纳米分散体的描述,该纳米分散体包含(a)在药物末端制剂中的成膜分子,(b)共乳化剂和(c)亲脂性组分,纳米分散体可通过(α)混合 组分(a),(b)和(c),直到获得均匀的透明液体,和(β)将步骤(α)中获得的液体加入到药物末端制剂的水相中,步骤(α)和 )在没有任何额外的能量供应的情况下进行。 根据本发明使用的纳米分散体适合用作药物活性剂的运输载体。